The solubility and stability of ginsenoside aPPD were determined, and the compound was formulated for oral gavage. The aPPD levels in blood and tissues following oral administration to nude mice were determined using liquid chromatography–mass spectrometry/mass spectrometry. The efficacy of ginsenoside aPPD was determined upon oral administration to nude mice bearing PC-3 human prostate cancer xenograft tumors.
Study shows that ginsenoside aPPD accumulated largely in the stomach and small intestine and was also present in the brain. This dose engendered a significant delay in PC-3 tumor growth, an increase in apoptotic index, and a decrease in Ki-67 levels.